Agensys was originally established in 1996 as UroGenesys, with $8 million in seed money to develop novel gene-based therapies for prostate cancer. After further research, the name was changed to Agensys, and the focus shifted to gene discovery and the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. Agensys was acquired by Astellas in 2018 for $537 million.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.allogene.com
Cougar Biotechnology, Inc. was a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology – specifically, drugs for prostate cancer, breast cancer and multiple myeloma. Cougar’s lead product, abiraterone acetate (Zytiga), was approved by the FDA and the European Union for the treatment of metastatic prostate cancer in 2011. Johnson & Johnson acquired Cougar in 2009 for $970 million.
Cell Design Labs
Founded in 2016, Cell Design Labs was a biotherapeutics company based in California’s Bay Area that focused on developing immunotherapies that deploy proprietary molecular modules targeting cancer and other diseases. The company developed two proprietary technology platforms: an “on switch” designed to modulate CAR T-cell activity using small molecules, and a synthetic gene expression system designed to respond to external cues, whose applications include engineering CAR T cells that require dual antigen recognition for activation. Cell Design Labs was acquired in December 2017 by Gilead Sciences for $567 million.
Kite Pharma was founded in Los Angeles by Arie Belldegrun in 2009 as a biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In 2017, Kite received approval for Yescarta™, the first FDA approved CAR T therapy for the treatment of adult patients with certain types of large B-cell lymphoma. Kite was acquired by Gilead in 2017 for $11.9 billion. Today, Kite, a Gilead company, is a leader in developing and commercializing autologous chimeric antigen receptor T-cell (CAR T) and T cell receptor (TCR) therapies for the treatment of cancer.www.kitepharma.com
Kronos Bio, a Boston-based biotechnology company, is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant (“undruggable”) cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.www.kronosbio.com
Neogene Therapeutics, Inc. is a biomedical company, based in Amsterdam, the Netherlands, dedicated to developing next-generation T cell therapies that target mutated proteins (neo-antigens) in cancer. Neogene is developing a minimally invasive and scalable platform that will enable targeting of neo-antigens occurring in individual patients with fully personalized and genetically engineered “Designer T cells” that have been optimized to seek and destroy tumor cells based on neo-antigens.
UroGen Pharma Ltd. (NASDAQ: URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in New York with research facilities in Israel.www.urogen.com
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model. Hubble is making daily disposable lenses affordable and convenient - important because daily disposable lenses are widely acknowledged as better for health and comfort. With Hubble, consumers don't have to choose anymore between overpaying and over wearing their lenses.www.hubblecontacts.com
Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. It combines Tishman-Speyer’s decades of global real estate development experience with Bellco Capital’s industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients. Breakthrough seeks to create and expand highly functional, well-located centers of excellence in the world’s key life science research centers.www.btprop.com
First Media is a global media company. Through social media platforms, digital, video, and cable television, First Media delivers targeted content to millennial women through their everyday go-to entertainment outlets. Its social platforms (Blossom, So Yummy and Blusher) have more than 80 million followers and over 1.5 billion monthly views across its social accounts, while its cable TV division operates the leading 24/7 linear baby network – BabyFirst – which is available in more than 120 million homes around the globe, in 33 countries and in 13 languages.first.media